Prepared: February 11, 2019
1 of 27
University of California, San Francisco
CURRICULUM VITAE
Name: Gregor Krings, MD, PhD
Position: Assistant Professor of Clinical Pathology, Step 4
Pathology
School of Medicine
Address: UCSF Department of Pathology
1825 4th Street
Box 4066, Room M2355
San Francisco, CA 94143-4066
Email: [email protected]
EDUCATION
1993 - 1994 Virginia State and
Polytechnic Institute,
Blacksburg, Virginia
1994 - 1997 University of
Georgia, Athens,
Georgia
B.A. Anthropology
1999 - 2008 Medical University of
South Carolina,
Charleston, South
Carolina
M.D. Medicine (Medical
Scientist Training
Program)
1999 - 2008 Medical University of
South Carolina,
Charleston, South
Carolina
Ph.D. Molecular and Cellular
Biology
Advisor: Deepak
Bastia
2008 - 2010 Massachusetts
General Hospital,
Boston,
Massachusetts
Resident
physician
Pathology
2010 - 2011 University of
California (UCSF),
San Francisco,
California
Resident
physician
Pathology
2011 - 2012 University of
California (UCSF),
San Francisco,
California
Clinical
fellow
Surgical and
Gastrointestinal/Liver
Pathology
Prepared: February 11, 2019
2 of 27
2012 - 2013 University of
California (UCSF),
San Francisco,
California
Clinical
research
fellow
Pathology Laboratory of
Barbara Panning
(Biochemistry &
Biophysics)
LICENSES, CERTIFICATION
2010 Medical licensure, California
2012 Board Certification in Anatomic Pathology, American Board of Pathology
PRINCIPAL POSITIONS HELD
1998 - 1999 Medical University of South Carolina,
Charleston, South Carolina
Post-graduate
researcher
Medicine,
Microbiology
2013 - 2014 University of California (UCSF), San
Francisco, California
Health Sciences
Clinical Instructor,
Breast Pathology
Pathology
2014 - present University of California (UCSF), San
Francisco, California
Assistant
Professor of
Clinical Pathology
Pathology
OTHER POSITIONS HELD CONCURRENTLY
2008 - 2010 Harvard Medical School, Boston,
Massachusetts
Clinical Fellow Pathology
2011 - 2013 University of California (UCSF), San
Francisco, California
Health Sciences
Clinical Instructor
Pathology
2013 - 2013 Beth Israel Deaconess Medical Center,
Harvard Medical School, Boston,
Massachusetts
Observer Breast
Pathology
(under Dr.
Stuart Schnitt)
HONORS AND AWARDS
2000 Summer Health Professionals
Research Fellowship Award
Medical University of South Carolina
2000 Medical Scientist Training Program
(National Institutes of Health) Training
Grant
Medical University of South Carolina
2001 Thomas W. Holbrook Award in
Pathology and Microbiology
Medical University of South Carolina
2003 2nd place prize (poster division,
Ph.D.), Student Research Day
Medical University of South Carolina
2004 1st place prize (oral division, Ph.D.),
Student Research Day
Medical University of South Carolina
Prepared: February 11, 2019
3 of 27
2005 2nd place prize (oral division, Ph.D.),
Student Research Day
Medical University of South Carolina
2006 Program for Excellence in Science American Association for the
Advancement of Science (AAAS)
2006 Provost Scholarship Medical University of South Carolina
2006 Alpha Omega Alpha medical honor
society
2007 Arnold P. Gold Humanism Honor
Society
2008 Distinguished Graduate Student Award Medical University of South Carolina
KEYWORDS/AREAS OF INTEREST Breast cancer, cancer genomics; neoplastic precursor lesions of the breast; fibroepithelial lesions; molecular diagnostics; molecular pathology.
CLINICAL ACTIVITIES
CLINICAL ACTIVITIES SUMMARY As a surgical pathologist with expertise in breast pathology, my clinical mission is to provide dedicated pathology services to UCSF patients with subspecialty focus on breast pathology. In this capacity, my practice primarily includes patients at the UCSF Carol Franc Buck Breast Care Center, and I attend on the Breast Pathology service at the Mission Bay campus. Given that UCSF is a tertiary care center with an internationally recognized clinical breast care service, these cases are often highly complex and require specialized expertise. In this role, I also provide diagnostic confirmation services for breast specimens obtained at other facilities from patients seeking to further their care at UCSF. I also provide diagnostic consultation services for second opinion of diagnostically challenging breast pathology cases sent by pathologists at other institutions. I attend and present at weekly multidisciplinary tumor board meetings for the clinical breast service at the Breast Care Center. I am a member of the UCSF Clinical Cancer Genomics Laboratory (CCGL). I provide diagnostic genetic molecular pathology services for tumors profiled with a targeted next generation DNA sequencing panel of cancer genes (UCSF500 cancer gene panel). My expertise includes the genomics of breast cancer, in addition to a wide variety of other tumor types. I also sign out ERBB2 fluorescence in situ hybridization (FISH) assays in breast and other cancers as needed. I attend and present at weekly multidisciplinary molecular tumor board meetings, at which genomics findings are discussed and integrated into a treatment plan. I attend on the Gastrointestinal/Liver Pathology service as a minor clinical focus, which primarily includes endoscopic and imaging-guided gastrointestinal biopsies, native and transplant liver biopsies. Additional surgical pathology services include rapid intraoperative frozen section coverage at Mission Bay and Mt. Zion hospitals and night call coverage at the Mission Bay campus.
Prepared: February 11, 2019
4 of 27
CLINICAL SERVICES
2013 - present UCSF Pathology, Breast (cluster A) and
Gastrointestinal/Liver (cluster B) services, Attending
pathologist
~60% total effort
(~95% clinical
service effort)
2015 - present Clinical Cancer Genomics Laboratory, UCSF500 Cancer
Gene Panel signout, Attending molecular pathologist
1/2 day per week
2016 - present Clinical Cancer Genomics Laboratory, HER2 FlSH signout,
Attending molecular pathologist
As needed
2012 - 2013 UCSF Pathology, overnight and weekend call
(intraoperative frozen section, rapid evaluation of donor
biopsies for transplantation, rush cases)
~5-6 weeks per
year
PROFESSIONAL ACTIVITIES
MEMBERSHIPS
1999 - 2000 American Medical Student Association (AMSA)
2006 - 2008 American College of Physicians (ACP), student member
2006 - 2007 American Association for the Advancement of Science (AAAS)
2006 - present Alpha Omega Alpha (AOA) Medical Honor Society
2007 - present Arnold P. Gold Humanism Honor Society
2008 - present College of American Pathologists (CAP)
2008 - 2010 Association for Molecular Pathology (AMP)
2013 - 2017 Association for Molecular Pathology (AMP)
2013 - present United States and Canadian Academy of Pathology (USCAP)
SERVICE TO PROFESSIONAL ORGANIZATIONS
2015 - present NRG Oncology Pathology Committee Core member
2017 - United States and Canadian Academy of Pathology
(USCAP) 106th Annual Meeting, San Antonio, TX
Moderator (invited),
Platform
presentations,
Breast Pathology
2018 - 2020 United States and Canadian Academy of Pathology
(USCAP) Annual Meeting (2018-2020 meetings)
Abstract Review
Board (invited 3-
year term), Breast
Pathology section
2018 - United States and Canadian Academy of Pathology
(USCAP) 107th Annual Meeting, Vancouver, British
Columbia
Moderator (invited),
Platform
presentations,
Breast Pathology
Prepared: February 11, 2019
5 of 27
SERVICE TO PROFESSIONAL PUBLICATIONS
2017 - Ad hoc reviewer, Human Pathology Case Reports
2017 - Ad hoc reviewer, Breast Cancer Research
INVITED PRESENTATIONS - INTERNATIONAL
2017 United States and Canadian Academy of Pathology
(USCAP), 106th Annual Meeting, San Antonio. "Genomic
Profiling of Secretory Carcinoma."
Presenter, platform
2018 United States and Canadian Academy of Pathology
(USCAP), 107th Annual Meeting, Vancouver, British
Columbia, Canada. "Genomic Profiling of Metaplastic
Carcinoma and Associated in Situ Carcinoma of the
Breast."
Presenter, platform
2019 United States and Canadian Academy of Pathology
(USCAP), 108th Annual Meeting, National Harbor,
Maryland. "Genetics of Flat Epithelial Atypia and Early
Neoplastic Progression in the Breast."
Presenter, platform
INVITED PRESENTATIONS - NATIONAL
2015 UCSF Postgraduate Course in Breast and Endocrine
Surgery, March 6-7th, 2015, San Francisco, CA
Presenter and
panel discussant
2015 "Fibroepithelial Lesions of the Breast", 31st Annual UCSF
Current Issues in Anatomic Pathology CME course, May
21st-23rd, 2015, San Francisco, CA
Lecturer
2016 "Solid Pattern Lesions of the Breast", 32nd Annual UCSF
Current Issues in Anatomic Pathology CME course, May
26-28th, 2016, San Francisco, CA
Lecturer
2018 "Updates on Diagnosis and Management of Borderline
and High Risk Breast Lesions on Core Needle Biopsy",
34th Annual UCSF Current Issues in Anatomic Pathology
CME course, May 24th-26th, 2018, San Francisco, CA
Lecturer
2019 "Spindle Cell Lesions of the Breast", 35th Annual UCSF
Current Issues in Anatomic Pathology CME course, May
23rd-25th, 2019, San Francisco, CA
Lecturer
CONTINUING EDUCATION AND PROFESSIONAL DEVELOPMENT ACTIVITIES
2010 "Gastrointestinal, Liver, and Pancreatic Pathology", Massachusetts General
Hospital, Boston, Massachusetts
2010 "Seminars in Pathology", 63rd Annual Convention of California Society of
Pathologists, San Francisco, California
Prepared: February 11, 2019
6 of 27
2011 United States and Canadian Academy of Pathology 100th Annual Meeting, San
Antonio, Texas
2012 United States and Canadian Academy of Pathology 101st Annual Meeting,
Vancouver, British Columbia
2012 UCSF Current Issues in Anatomic Pathology, San Francisco, California
2013 United States and Canadian Academy of Pathology 102nd Annual Meeting,
Baltimore, Maryland
2013 66th Annual Convention of California Society of Pathologists, San Francisco,
California
2013 "Breast Pathology. Current Concepts and Controversies", Harvard Medical
School, Boston, Massachusetts
2013 San Antonio Breast Cancer Symposium, San Antonio, Texas
2014 United States and Canadian Academy of Pathology 103rd Annual Meeting, San
Diego, California
2014 San Antonio Breast Cancer Symposium, San Antonio, Texas
2015 United States and Canadian Academy of Pathology 104th Annual Meeting,
Boston, Massachusetts
2015 "Updates in the Changing World of Breast Pathology", California Tumor Tissue
Registry, San Francisco, California
2015 Current Issues in Anatomic Pathology, San Francisco, California
2016 United States and Canadian Academy of Pathology 105th Annual Meeting,
Seattle, Washington
2016 Current Issues in Anatomic Pathology, San Francisco, California
2017 United States and Canadian Academy of Pathology 106th Annual Meeting, San
Antonio, TX
2018 UCSF Current Issues in Anatomic Pathology, San Francisco, California
UNIVERSITY AND PUBLIC SERVICE
SERVICE ACTIVITIES SUMMARY I serve on the core committee tasked with organizing an annual UCSF Pathology research retreat (2017, 2018) aimed at highlighting the broad scope of basic science and clinical research in the Pathology Department. As the Mission Bay campus site director for the UCSF School of Medicine pathology rotation for medical students, my responsibilities have included designing, implementing and supervising a practical surgical pathology experience and serving as the primary point person for medical students during their rotation through the Pathology department at Mission Bay.
Prepared: February 11, 2019
7 of 27
I organize and lead the monthly orientation of Anatomic Pathology residents and fellows rotating onto the Breast Pathology service at the Mission Bay hospital. In preparation for the move to the Mission Bay hospital, I served as the faculty lead for visual media for the new site, being responsible for evaluation of visual media needs (photography, streaming video) for clinical gross specimen photography. I continue to serve in this role for the Mission Bay campus as needed.
SCHOOL OF MEDICINE
2015 - 2018 UCSF School of Medicine, Pathology rotation Site director for
medical students,
Mission Bay
campus
DEPARTMENTAL SERVICE
2019 -
Breast Pathology Fellowship, UCSF Department of
Pathology
Director
2017 - UCSF Department of Pathology, Research Retreat Organizational
core committee
member
2017 - 2017 UCSF Department of Pathology, proctoring of clinical
instructor in breast pathology (Dr. Gregory Bean)
Clinical proctor
2016 - 2016 UCSF Department of Pathology/Clinical Cancer
Genomics Laboratory
Faculty search
committee
member
2016 - 2016 UCF Department of Pathology, Workflow integration of
molecular pathology reporting with surgical pathology
Co-lead
2015 - 2018 UCSF School of Medicine, Pathology rotation Site director for
medical students,
Mission Bay
campus
2014 - Project faculty lead for gross specimen photography,
Mission Bay Hospital, UCSF Department of Pathology.
Faculty Lead
2014 - Breast pathology service resident and fellow orientation,
UCSF Department of Pathology
Lead
Prepared: February 11, 2019
8 of 27
2012 - Surgical Pathology Quarterly Meeting, UCSF Department
of Pathology
Participant
COMMUNITY AND PUBLIC SERVICE
2018 - East Bay German International School Volunteer, school
and community
events
TEACHING AND MENTORING
TEACHING SUMMARY Residency and fellowship teaching: My primary teaching activity is diagnostic surgical pathology with a primary breast and secondary gastrointestinal focus to junior and senior residents, surgical pathology fellows, and breast and GI/liver subspecialty fellows. I also teach breast surgery fellows and visiting scholars rotating through our department. Teaching is primarily microscope-based during daily clinical signout and also includes gross specimen evaluation and dissection. I also teach cancer clinical genomics via the UCSF500 targeted next generation sequencing assay on an ad hoc basis. I present a series of formal diagnostic breast pathology lectures to pathology residents and fellows for the Resident Teaching Conference (RTC) curriculum, a year-round lecture series that covers all major aspects of modern surgical pathology. I contribute approximately 50% of the breast pathology lectures in this series. In addition, I prepare breast pathology slide sets and practical slide teaching sessions for housestaff. Medical student teaching: I have served as a small group leader in the Mechanisms, Methods, and Malignancies (M3) section of the School of Medicine (SOM) curriculum and as laboratory instructor for the SOM GAP labs. I also assist in teaching the surgical pathology component of the Medical Student Pathology Elective for students rotating on the surgical pathology service. Continuing Medical Education (CME) teaching: I lecture to pathologists at the annual UCSF 'Current Issues in Anatomic Pathology' CME meeting on an invited basis.
FORMAL TEACHING
Academic Yr Course No. & Title Teaching
Contribution
School Class
Size
2010 - 2011 Interdepartmental
Studies (IDS) 101:
Prologue
Laboratory
instructor/facilitator:
acute and chronic
inflammation (1
session), neoplasia
(1 session)
Medicine 30-40
Prepared: February 11, 2019
9 of 27
Academic Yr Course No. & Title Teaching
Contribution
School Class
Size
2010 - 2011 Interdepartmental
Studies (IDS) 102B:
Organ Systems:
Topics in Renal and
Pulmonary
Pathophysiology
Laboratory
instructor/facilitator:
glomerular diseases
(1 session)
Medicine 30-40
2010 - 2011 Interdepartmental
Studies (IDS) 103A:
Metabolism and
Nutrition
Laboratory
instructor/facilitator:
upper
gastrointestinal
system (1 session)
Medicine 30-40
2011 - 2012 Interdepartmental
Studies (IDS) 103A:
Metabolism and
Nutrition
Laboratory
instructor/facilitator:
liver (1 session),
lower gastrointestinal
system (1 session)
Medicine 30-40
2012 - 2013 Interdepartmental
Studies (IDS) 106:
Mechanisms,
Methods, and
Malignancies (M3)
Small group leader:
Classification of
Neoplasms (1
session)
Medicine 13
2012 - 2013 Interdepartmental
Studies (IDS) 102B:
Organ Systems:
Topics in Renal and
Pulmonary
Pathophysiology
Laboratory
instructor/facilitator:
Obstructive and
restrictive pulmonary
diseases (1 session)
Medicine 15-25
2012 - 2013 Interdepartmental
Studies (IDS) 103A:
Metabolism and
Nutrition
Laboratory
instructor/facilitator:
liver (1 session),
lower gastrointestinal
system (1 session),
upper
gastrointestinal
system (1 session),
pancreas (1 session)
Medicine 50-75
2014 - 2015 Interdepartmental
Studies (IDS):
Mechanisms,
Methods, and
Malignancies (M3)
Small group leader:
Classification of
Neoplasms (1
session)
Medicine 10-15
Prepared: February 11, 2019
10 of 27
Academic Yr Course No. & Title Teaching
Contribution
School Class
Size
2015 - 2016 Mechanisms,
Methods and
Malignancies (M3)
Small group leader:
Classification of
Neoplasms (1
session)
Medicine 10-15
2015 - 2016 Breast Cancer GAP
lab
Laboratory instructor Medicine ~80-
100
2016 - 2017 Breast Cancer GAP
lab
Laboratory instructor Medicine ~80-
100
2016 - 2017 Prostate Cancer GAP
lab
Laboratory instructor Medicine ~80-
100
2016 - 2017 Mechanisms,
Methods and
Malignancies (M3),
UCSF School of
Medicine
Small group leader:
Classification of
Neoplasms (1
session)
Medicine 10-15
INFORMAL TEACHING
2008 - 2010 Department of Pathology, Massachusetts General Hospital, Boston,
Massachusetts: Gross and microscopic pathology to rotating medical students
and junior pathology residents
2010 - 2011 Department of Pathology, University of California (UCSF), San Francisco,
California: Gross and microscopic pathology to rotating medical students
2011 - 2012 Department of Pathology, University of California (UCSF), San Francisco,
California: Gross and microscopic pathology to junior pathology residents
(including prepared slide sessions)
2011 - 2011 Department of Pathology, University of California (UCSF), San Francisco,
California: Basic liver pathology to clinical hepatology fellows at monthly "Liver
Pathology" meetings
2012 - 2013 Department of Pathology, University of California (UCSF), San Francisco,
California: Supervised laboratory work of Catherine Carbone, a post-graduate
researcher in the laboratory of Dr. Barbara Panning (Department of
Biochemistry and Biophysics)
2013 - present Department of Pathology, University of California (UCSF), San Francisco,
California: Diagnostic gross and microscopic surgical pathology to pathology
residents and fellows during daily signout, prepared slide sessions
2016 - present Department of Pathology, University of California (UCSF), San Francisco,
California: Cancer genomics using the UCSF500 targeted next-generation
sequencing panel to residents and fellows.
Prepared: February 11, 2019
11 of 27
MENTORING SUMMARY Teaching and mentoring pathology residents and fellows is an important component of my practice, including diagnostic surgical pathology and pathology research projects. I also serve as an ad hoc proctor for UCSF clinical instructors in breast pathology and have mentored visiting high school students and visiting faculty from other institutions. As a research project mentor for residents and fellows, I provide guidance on project design, experimentation, data analysis and presentation, and manuscript preparation and writing. Projects have been presented by the mentees at the San Antonio Breast Cancer Symposium and United States and Canadian Academy of Pathology (USCAP) meetings, as well as local and university conferences, as poster or platform presentations. A project on TERT promoter mutations in combined hepatocellular-cholangiocarcinomas received first runner-up for the prestigious Hans Popper Best Trainee award at the 2014 USCAP meeting (Dr. Tsokos). Many of these projects have resulted in published manuscripts in top-tier pathology journals, and others are currently preparation. I serve as a faculty mentor for residents presenting at the departmental Mechanisms of Disease (MOD) conference, a core feature of our residency/fellowship curriculum at which residents and fellows biannually present a scientific/medical topic of interest to the entire department in a formal lecture format.
PREDOCTORAL STUDENTS SUPERVISED OR MENTORED
Dates Name Program or
School
Mentor Type Role Current
Position
2016 - Tianming Chu Project Mentor Summer research
project mentor
High school
student
2017 - Tianming Chu Project Mentor Summer research
project mentor
High school
student
2012 - 2013 Catherine
Carbone
Project Mentor Research project
supervisor
Graduate
student,
UCSF
POSTDOCTORAL FELLOWS AND RESIDENTS MENTORED
Dates Name Fellow Mentor Role Faculty Role Current
Position
2014 - 2017 Christos
Tsokos, MD
PhD
Anatomic
Pathology
resident and
surgical
pathology
fellow
Research/Scholarly
Mentor, Project
Mentor, Career
Mentor
Research project
mentor
Research
fellow, MGH
Pathology (R.
Kingston lab),
Boston, MA
2015 - 2017 Su-Yang Liu,
MD PhD
Anatomic
pathology
resident
Research/Scholarly
Mentor, Project
Mentor
MOD mentor and
research project
mentor
Research
fellow, UCSF
Prepared: February 11, 2019
12 of 27
Dates Name Fellow Mentor Role Faculty Role Current
Position
2014 - 2017 Dianna Ng, MD Anatomy
pathology
resident
Research/Scholarly
Mentor, Project
Mentor
Project co-mentor Assistant
Professor,
UCSF/ZSFG
H
2015 - Emily Chan,
MD PhD
Anatomic
Pathology
resident
Project Mentor Project mentor
(MOD)
Clinical
instructor,
UCSF
2015 - present Gregory Bean,
MD PhD
Anatomic
Pathology
resident,
Breast and
surgical
pathology
fellow
Research/Scholarly
Mentor, Project
Mentor, Career
Mentor
MOD mentor and
research project
mentor
Assistant
Professor,
Stanford
University,
Stanford, CA
2016 - John
Cannatella, MD
Anatomic
Pathology
resident
Project Mentor Project mentor
(MOD)
Pathology
resident,
UCSF
2016 - present Eliah Shamir,
MD PhD
Anatomic
Pathology
resident,
Breast and
surgical
pathology
fellow
Research/Scholarly
Mentor, Project
Mentor
Research project
mentor and MOD
mentor
Breast and
surgical
pathology
fellow, UCSF
2017 - present Jeanette Ruiz,
MD
Anatomic
pathology
resident
Research/Scholarly
Mentor, Project
Mentor
Research project
mentor
Surgical
Pathology
fellow, UCSF
FACULTY MENTORING
Dates Name Position while
Mentored
Mentor Type Mentoring Role Current
Position
2017 - Gregory Bean,
MD PhD
Clinical
Instructor,
UCSF
Research/Scholarly
Mentor, Project
Mentor, Career
Mentor, Co-
Mentor/Clinical
Mentor
Clinical, career, and
research project
mentor
Assistant
Professor,
Stanford
VISITING FACULTY MENTORED
2014 - 2014 Cynthia Osorio, MD
(Avon Scholar)
Antonio Prudente Foundation, AC Camargo Cancer
Center, Department of Pathology, Sao Paolo, Brazil.
Prepared: February 11, 2019
13 of 27
2018 - Minlin Kim Seoul National University, Bundang Hospital, Seoul,
South Korea.
RESEARCH AND CREATIVE ACTIVITIES
RESEARCH AND CREATIVE ACTIVITIES SUMMARY My overall research mission is to translate insights in cancer biology towards improvements in breast cancer diagnostics and treatment. I am especially interested in breast cancer genomics and the diagnostic integration of molecular pathology with histopathology for meaningful classification of breast tumors. In this context, I have published work on the genomics of breast secretory carcinomas and their intrinsic relationship to salivary gland analogues (Mod Pathol. 2017), the genomics of metaplastic breast carcinoma histologic subtypes (Mod Pathol. 2018), and the genetics of mucoepidermoid carcinomas (Histopathology 2018). Ongoing work in this area includes additional genotype-phenotype correlations in metaplastic breast carcinomas and molecular characterization of other salivary gland-like carcinomas, such as pleomorphic adenomas of the breast. As a member of The Cancer Genome Atlas (TCGA) breast pathology expert panel, I was involved in a recently published integrative study correlating the morphologic and molecular features of breast cancers using a variety of platforms (J Pathol. 2017). Another research interest focuses on neoplastic precursor lesions, cancer risk and tumor progression pathways. Published and ongoing work in this area includes phyllodes tumor genetics, deep sequencing of paired precursor lesions in the low grade epithelial neoplasia pathway, and the relationship of classic lobular carcinoma in situ (LCIS) with more aggressive variants and invasive breast cancer (Am. J. Surg. Pathol. 2018). I have an interest in fibroepithelial lesions and have published work on the genetics of malignant phyllodes tumors, highlighting recurrently aberrant oncogenic pathways, tumor progression and genetic heterogeneity of these rare tumors (Mod Pathol. 2016). I am collaborating with Dr. Christopher Benz (Buck Institute for Research on Aging) to elucidate the role of IGF1R polymorphisms in breast cancer risk with morphologic, immunophenotypic, and molecular correlation in benign breast tissue. In collaboration with Dr. Andrei Goga (Medicine and Tissue Biology, UCSF), I have contributed to seminal work on the role of fatty acid oxidation and metabolomics in triple negative breast cancer (Nat Med. 2016). Ongoing collaborative work with Dr. Goga’s group involves the role of lipolysis in breast cancer growth and invasion (bioRxiv 277939). I have collaborated with Drs. Laura Esserman (Surgery, UCSF) and Pamela Munster (Oncology, UCSF) in studying the role of the immune system and microenvironment in breast cancer growth and development (Breast Cancer Res Treat. 2017, Oncotarget 2017). Ongoing collaborative work with Dr. Esserman in this area involves the effects of direct Pembrolizumab injections on pathobiology and tumor-directed immune response in patients with ductal carcinoma in situ. Other collaborations include a multi-institutional study non-classical HER2 patterns in breast cancer (Mod. Pathol. 2017), studies of drug delivery approaches in breast cancer (Laura Vant Veer, Breast Cancer Res. 2017; Pamela Munster, Sci Rep. 2018), molecular mechanisms of acquired drug resistance to targeted therapies (Sourav Bandyopadhyay, Nat. Med., 2018), and transcriptomics of cancer-adjacent normal tissues (Atul Butte, Nat Commun. 2017). I am a collaborator in clinically-directed studies aimed at improving breast cancer diagnostics and treatment. I am a study pathologist for the I-SPY2 clinical trial (Dr. Laura Esserman), an adaptive multicenter effort to personalize breast neoadjuvant breast cancer treatment (N Engl J Med. 2016). I am also a member of the Athena Breast Health Network Pathology working group. A collaborative effort with this group identified intratumoral ER heterogeneity as a
Prepared: February 11, 2019
14 of 27
predictive factor for an increased long-term risk of fatal breast cancer in patients enrolled in the STO-3 trial (J Natl Cancer Inst. 2018). I previously served as study pathologist in a multicenter study that aims to use novel imaging models based on lesional water, protein, and lipid composition (3CB) in diagnostic mammography to improve the specificity of breast cancer diagnosis and decrease unnecessary biopsies (Dr. John Shepherd).
RESEARCH AWARDS - CURRENT
1. I-SPY2 Trial Study pathologist 3 % effort Esserman (PI)
QuantumLeap Health Care Collaborative 01/01/2014 06/30/2020
I-SPY 2 Trial (Investigation of Serial studies to predict
your therapeutic response with imaging and molecular
analysis)
$ 1,894,595 total
The I-SPY 2 TRIAL is a Phase II, randomized, controlled, multi-center trial for women with
newly diagnosed, locally advanced breast cancer (Stage II/III). The trial employs an adaptive
design, matching experimental therapies with patients based on the use of biomarkers,
investigating whether new therapies can be added to standard chemotherapy or whether they
may replace certain components of standard chemotherapy in the neoadjuvant setting.
Therapies that are found effective can move onto a more focused Phase III registration trial.
Study pathologist, including histopathologic evaluation of pre- and post-treatment cancers,
residual cancer burden (RCB) grading, tumor evaluation for molecular testing
2. PI Krings (PI)
UCSF Department of Pathology 5/30/2017 Present
Genomic Analysis of Non-Classic Lobular Carcinoma in
Situ Variants and Synchronous Invasive Lobular
Carcinoma
$ 12,600 total
3. PI Krings (PI)
UCSF Department of Pathology 5/2/2018 Present
Genomic Analysis of Chondroid Matrix-Producing Breast
Carcinomas: Genotype-Phenotype Correlation
$ 11,560 total
4. PI Krings (PI)
UCSF Department of Pathology 11/5/2018 Present
Genomic Analysis of Basaloid Breast Carcinomas
Reveals Distinct Genetics from Other Triple Negative
Breast Cancers
$ 13,216 total
Prepared: February 11, 2019
15 of 27
RESEARCH AWARDS - PAST
1. UCSF500 Cancer Gene Pilot
Program
PI Krings, Gregor
(PI)
UCSF Department of Pathology/Clinical Cancer
Genomics Laboratory
1/12/2015
Characterizing the Molecular Progression of Low-grade
Intraductal Neoplasia in the Breast
$ 16,500 total
2. UCSF500 Cancer Gene Pilot
Program
Co-PI Jen, Kuang-Yu
(PI)
UCSF Department of Pathology/Clinical Cancer Genomic
Laboratory
1/12/2015
Mutational Landscape of Bilateral Lobular Carcinomas $ 13,000 total
3. UCSF500 Cancer Gene Pilot
Program
Co-PI Ferrell, L. (PI)
UCSF Department of Pathology/Clinical Cancer Genomic
Laboratory
1/12/2015
Genomic analysis of combined hepatocellular-
cholangiocarcinoma
$ 11,000 total
4. UCSF500 Cancer Gene Pilot
Program
Co-PI Vohra, P. (PI)
UCSF Department of Pathology/Clinical Cancer
Genomics Laboratory
1/12/2015
Genomic characterization of metaplastic carcinomas of
the breast
$ 16,500 total
5. UCSF500 Cancer Gene Pilot
Program
Co-PI Chen, Y-Y (PI)
UCSF Department of Pathology/Clinical Cancer
Genomics Laboratory
1/12/2015
Genomic evolution of metastatic progression in breast
cancer
$ 16,500 total
6. 5RO1CA166945-03 Study pathologist 10 % effort Shepherd (PI)
Prepared: February 11, 2019
16 of 27
National Institutes of Health 3/6/2013 2/28/2018
Lesion Composition and Qualitative Imaging Analysis on
Breast Cancer
This project aims to use novel imaging models based on lesional water, protein, and lipid
composition (3CB) in diagnostic mammography to improve the specificity of breast cancer
diagnosis and decrease unnecessary biopsies.
Provide all pathology support and expertise for the project.
PEER REVIEWED PUBLICATIONS
1. Virella G., Koskinen S., Krings G., Onorato J.M., Thorpe S.R., and Lopes-Virella M. Immunochemical characterization of purified human oxidized low-density lipoprotein antibodies. Clin. Immunol. 2000;95: 135-144. PMID: 10779407
2. Vielma, S.A., Krings, G., and Lopes-Virella, M.F. Chlamydophila pneumoniae induces ICAM-1 expression in human aortic endothelial cells via protein kinase C-dependent activation of nuclear factor-kappaB. Circ. Res. 2003; 92:1130-1137.PMID: 12714566
3. Krings, G. and Bastia, D. swi1- and swi3-dependent and independent replication fork arrest at the ribosomal DNA of Schizosaccharomyces pombe. Proc. Natl. Acad. Sci. U.S.A. 2004; 101: 14085-14090. PMID: 15371597
4. Krings, G. and Bastia, D. Sap1p binds to Ter1 at the ribosomal DNA of Schizosaccharomyces pombe and causes polar replication fork arrest. J. Biol. Chem. 2005;280:39135-39142. PMID: 16195226
5. Krings, G. and Bastia, D. Molecular architecture of a eukaryotic DNA terminus-terminator protein complex. Mol. Cell. Biol. 2006;26:8061-8074. PMID: 16940176
6. Bastia, D., Zzaman S., Krings, G., Saxena, M., Peng, X., and Greenberg, M.M. Replication termination mechanism as revealed by Tus-mediated polar arrest of a sliding helicase. Proc. Natl. Acad. Sci. U.S.A. 2008;105:12831-12836. PMID: 18708526
7. Vagefi, P.A., Stangenberg, L., Krings, G., Forcione, D.G., Fernandez-del Castillo, C., and Wargo, J.A. Ocular melanoma metastatic to the pancreas following a 28 year disease-free interval. Surgery 2010;148:151-154.PMID: 19744448
8. Krings, G., Ramachandran, R, Jain, D., Wu, T.-T., Yeh, M.W., Torbenson, M., and Kakar, S. (2013) Immunohistochemical pitfalls and the importance of glypican 3 and arginase in the diagnosis of scirrhous hepatocellular carcinoma. Modern Pathology 2013;26:782-791. PMID: 23348905
9. Krings, G.*†, Can, B.*, and Ferrell, L. Aberrant Centrizonal Features in Chronic Hepatic Venous Outflow Obstruction: Centrilobular Mimicry of Portal-based Disease. Am. J. Surg. Pathol. 2014; 38(2):205-214. PMID: 24418854 *Co-first authors, †Corresponding author
10. Krings, G.*, Nystrom, M., Mehdi, I., Vohra, P., and Chen, Y-Y. Diagnostic Utility and Sensitivities of GATA3 Antibodies in Triple Negative Breast Cancer. Hum Pathol 2014;45(11):2225-32. PMID: 25150746 *Corresponding author
11. Moh, M., Krings, G., Ates, D., Aysal, A., Kim, G.E. and Rabban, J.T. SATB2 Expression Distinguishes Ovarian Metastases of Colorectal and Appendiceal Origin From Primary Ovarian Tumors of Mucinous or Endometrioid Type. Am J Surg Pathol. 2016 Mar;40(3):419-32. PMID: 26551622
Prepared: February 11, 2019
17 of 27
12. McKelvie, P.A., Climent, F., Krings, G., Hasserjian, R.P., Abramson, J.S., Pilch, B.Z., Harris, N.L., Ferry, J.A., Zukerberg, L.R., and Sohani, A.R. Small-cell predominant extranodal NK/T-cell lymphoma, nasal type: Clinicopathologic analysis of a series of cases diagnosed in a Western population. Histopathology. 2016 Oct;69(4):667-79. PMID: 27144366
13. Camarda, R., Zhou, A.Y., Kohnz, R.A., Balakrishnan, S., Mahieu, C., Anderton, B., Eyob, H., Kajimura, S., Tward, A., Krings, G., Nomura, D.K., and Goga, A. Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer. Nat Med. 2016 Apr;22(4):427-32. PMID: 26950360
14. Myers, S.A., Peddada, S., Chatterjee, N., Freidreich, T., Tomoda, K., Krings, G., Thomas, S., Broeker, M. Maynard, J., Thomson, M, Pollard, K., Yamanaka, S., Burlingame, A.L., and Panning, B. SOX2 O-GlcNAcylation alters its protein-protein interactions and genomic occupancy to modulate gene expression in pluripotent cells. Elife. 2016 Mar 7;5:e10647. doi: 10.7554/eLife.10647. PMID: 26949256
15. Liu, S-Y., Joseph, N.M., Ravindranathan, A., Stohr, B., Greenland, N., Vohra, P., Hosfield, E., Yeh, I., Talevich, E., Onodera, C., Van Ziffle, J., Grenert, J.P., Bastian, B., 4, Chen, Y-Y., and Krings, G*. Genomic Profiling of Malignant Phyllodes Tumors Reveals Aberrations in FGFR1 and PI-3 Kinase/RAS Signaling Pathways and Provides Insights into Intratumoral Heterogeneity. Mod Pathol. 2016 Sep;29(9):1012-27. PMID: 27255162 *Corresponding author
16. Tsokos, C.G., Krings, G., Yilmaz, F., Ferrell, L.D., and Gill, R.M. Proliferative Index Facilitates Distinction Between Benign Biliary Lesions and Intrahepatic Cholangiocarcinoma. Hum Pathol. 2016 Nov;57:61-67. PMID: 27396933
17. Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ; I-SPY 2 Investigators. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. N Engl J Med. 2016 Jul 7;375(1):23-34.PMID: 27406347
18. Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA; I-SPY 2 Investigators. Adaptive Randomization of Neratinib in Early Breast Cancer. N Engl J Med. 2016 Jul 7;375(1):11-22. PMID: 27406346
19. Ballard M, Jalikis F, Krings G, Schmidt RA, Chen YY, Rendi MH, Dintzis SM, Jensen KC, West RB, Sibley RK, Troxell ML, Allison KH. 'Non-classical' HER2 FISH results in breast cancer: a multi-institutional study. Mod Pathol. 2017 Feb;30(2):227-235. PMID: 27739440
20. Campbell MJ, Baehner F, O'Meara T, Ojukwu E, Han B, Mukhtar R, Tandon V, Endicott M, Zhu Z, Wong J, Krings G, Au A, Gray JW, Esserman L. Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast. Breast Cancer Res Treat. 2017 Jan;161(1):17-28. PMID: 27785654
Prepared: February 11, 2019
18 of 27
21. Heng YJ, Lester SC, Tse GMK, Factor RE, Allison KH, Collins LC, Chen Y-Y, Jensen KC, Johnson NB, Jeong JC, Punjabi R, Shin SJ, Singh K, Krings G, Eberhard DA, Tan PH, Korski K, Waldman F, Gutman DA, Sanders M, Reis-Filho JS, Flanagan SR, Gendoo DM, Chen G, Kains BH, Ciriello G, Hoadley KA, Perou CM, and Beck AH. The molecular basis of breast cancer pathologic phenotypes. J Pathol. 2017 Feb;241(3):375-391. PMID: 27861902
22. Krings, G.*, Joseph, N., Bean, G., Solomon, D., Onodera, C., Talevich, E., Yeh, I., Grenert, J.P., Hosfield, E., Crawford, E.D., Jordan, R.C., van Zante, A., Zaloudek, C.Z., Shin, S.J., and Chen, Y-Y. Genomic Profiling of Breast Secretory Carcinomas Reveals Distinct Genetics from Other Breast Cancers and Similarity to Mammary Analogue Secretory Carcinomas. Mod Pathol. 2017 Aug;30(8):1086-1099. doi: 10.1038/modpathol.2017.32. Epub 2017 May 26. PMID: 28548128 *Corresponding author
23. Bartelink, I.H., Prideaux, B., Krings, G., Wilmes, L., Lee, E.P.R., Pan, B., Hann, B., Coppe, J.P., Heditsian, D., Swigart-Brown, L., Jones, E.F., Magnitsky, S., Keizer, R., deVries, N., Rosing, H., Pawlowska, N., Thomas, S., Dhawan, M., Aggarwal, R., Munster, P.N., Esserman, L.J., Ruan, W., Wu, A.H.B., Yee, D., Dartois,V., Savic, R.M., Wolf, D.M., and vant Veer, L. Heterogeneous Drug Penetrance of Veliparib and Carboplatin Measured in Triple Negative Breast Tumors. Breast Cancer Res. 2017 Sep 11; 19(1):107. PMID: 28893315
24. Aran, D., Camarda, R., Odegaard, J., Paik, H., Oskotsky, B., Krings, G., Goga, A., Sirota, M., and Butte, A.J. Comprehensive Analysis of Normal Adjacent to Tumor Transcriptomes. Nat Commun. 2017 Oct 20;8(1):1077.PMID: 29057876
25. Terranova-Barberio M., Thomas, S. Ali, N., Pawlowska, N., Park, J., Krings, G., Rosenblum, M.D., Budillon, A., and Munster, P.N. HDAC inhibition potentiates immunotherapy in triple negative breast cancer. Oncotarget. 2017 Dec 12;8(69):114156-114172. PMID: 29371976
26. Park, J., Thomas, S., Zhong, A.Y., Wolfe, A.R., Krings, G., Terranova-Barberio. M., Pawlowska, N., Benet, L.Z., and Munster, P.N.Local delivery of hormonal therapy with silastic tubing for prevention and treatment of breast cancer. Sci Rep. 2018 Jan 8;8(1):92. PMID: 29311658
27. Lindstrom, L.S., Yau, C., Czene, K., Thompson, C.K., Hoadley, K.A., van’ t Veer, L.J.,
Balassanian, R., Bishop, J.W., Carpenter, P.M., Chen, Y-Y., Datnow, B., Hasteh, F.,
Krings, G., Lin, F., Zhang, Y., Nordenskjold, B., Sta l, O., Benz, C.C., Fornander, T.,
Borowsky, A.D., Esserman, L.J.; for the STO Trialists Group.Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer. J Natl Cancer Inst. 2018 Jan 19. doi: 10.1093/jnci/djx270. [Epub ahead of print] PMID: 29361175
28. Cohen, J., Sabnis, A.J., Krings, G., Cho, S.-J., Horvai, A.E., and Davis, J.D. EWSR1-NFATC2 Gene Fusion in a Soft Tissue Tumor with Epithelioid Round Cell Morphology and Abundant Stroma: A Case Report and Review of the Literature. Hum Pathol. 2018 Apr 4. pii: S0046-8177(18)30097-2. PMID: 29626598
29. Krings, G.* and Chen, Y-Y. Genomic Profiling of Metaplastic Breast Carcinomas Reveals Genetic Heterogeneity and Relationship to Ductal Carcinoma. Mod Pathol. 2018 Jun 26. doi: 10.1038/s41379-018-0081-z. [Epub ahead of print] PMID: 29946183 *Corresponding author (Journal cover, November 2018)
Prepared: February 11, 2019
19 of 27
30. Shamir, E.R., Devine, W.P., Umetsu, S.E., Krings, G., Federman, S., Cho, S.-J., Saunders, T.A., Jen, K.-Y., Bergsland, E., Jones, K., Kim, G.E., Kakar, S., Chiu, C.Y., and Joseph, N.M. Identification of high-risk human papillomavirus and Rb/E2F pathway genomic alterations in mutually exclusive subsets of colorectal neuroendocrine carcinoma. Mod Pathol 2018 Sep 20. doi: 10.1038/s41379-018-0131-6. [Epub ahead of print] PMID: 30237525
31. Bean, G.R., Anderson, J., Sangoi, A.R., Krings, G.*, and Garg, K.* DICER1 mutations are frequent in müllerian adenosarcomas and are independent of rhabdomyosarcomatous differentiation. Mod Pathol. 2018 Sep 28. doi: 10.1038/s41379-018-0132-5. [Epub ahead of print] PMID: 30380176 *co-senior author
32. Bean, G.R., Krings, G., Otis, C.N., Solomon, D.A., García, J.J., van Zante, A., Camelo-Piragua, S., Van Ziffle, J., Chen, Y-Y. CRTC1-MAML2 Fusion in Mucoepidermoid Carcinoma of the Breast. Histopathology. 2018 Oct 31. doi: 10.1111/his.13779. [Epub ahead of print] PMID: 30380176
33. Shah, K.N., Bhatt, R., Rotow, J., Rohrberg. J., Olivas, V., Wang, V.E., Hemmati, G., Martins, M.M., Maynard, A., Kuhn, J., Galeas, J., Donnella, H.J., Kaushik, S., Ku, A., Dumont, S., Krings, G., Haringsma, H.J., Robillard, L., Simmons, A.D.,Harding, T.C., McCormick, F., Goga, A., Blakely, C.M., Bivona, T.G., and Bandyopadhyay, S. Aurora kinase A drives the evolution of resistance to third generation EGFR inhibitors in lung cancer. Nat Med. 2018 Nov 26. doi: 10.1038/s41591-018-0264-7. [Epub ahead of print] PMID: 30478424
34. Shamir, E.R., Chen, Y-Y., Chu, T., Pekmezci, M., Rabban, J.R., and Krings, G.* Pleomorphic and Florid Lobular Carcinoma in Situ Variants of the Breast: A Clinicopathologic Study of 85 Cases With and Without Invasive Carcinoma from a Single Academic Center. Am J Surg Pathol. 2018 Nov 27. doi: 10.1097/PAS.0000000000001191. [Epub ahead of print] PMID: 30489319 *Corresponding author
35. Joseph, N.M., Tsokos, C.G., Umetsu, S.E., Shain, A.H., Kelley, R.K., Onodera, C., Bowman, S., Talevich, E., Ferrell, L.D., Kakar, S., Krings, G. Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma. J Pathol. 2019 Jan 28. doi: 10.1002/path.5243. [Epub ahead of print] PMID: 30690729
REVIEW ARTICLES
1. Krings, G., Bean, G.R., and Chen, Y-Y. Fibroepithelial Lesions - The WHO Spectrum. Semin Diagn Pathol. 2017 Sep;34(5):438-452. doi: 10.1053/j.semdp.2017.05.006. Epub 2017 May 28. Invited review. PMID: 28688536
2. Krings, G., McIntire, P., and Shin, S.J. Myofibroblastic, Fibroblastic, and Myoid Lesions of the Breast. Semin Diagn Pathol. 2017 Sep;34(5):427-437. doi: 10.1053/j.semdp.2017.05.010. Epub 2017 May 28. Invited review. PMID: 28751104
BOOKS AND CHAPTERS
1. Krings, G. and Chen, Y-Y. (2016). Fibroepithelial Lesions. In Shin, S (Ed.), Comprehensive Guide to Core Needle Biopsies of the Breast. New York, NY: Springer.
2. Vohra, P., Krings, G., and Chen, Y-Y. (2016). Less Common Triple Negative Breast Cancers. In Shin, S (Ed.), Comprehensive Guide to Core Needle Biopsies of the Breast. New York, NY: Springer.
Prepared: February 11, 2019
20 of 27
3. Krings, G., Rabban, J.T., and Shin, S.J. (2016). Mesenchymal Neoplasms of the Breast, In Dabbs, DJ (Ed.), Breast Pathology (2nd edition). Expert Consult series. Philadelphia, PA: Elsevier.
4. Krings, G., Sorenson, P., Yang, W., Chen, Y-Y. Secretory Carcinoma, In WHO Classification of Tumours of the Breast (5th edition). Lyon, France: IARC. (in preparation, invited author)
CONFERENCE ABSTRACTS
1. Vielma, S.A., Krings, G., and Lopes-Virella, M.F. Protein Kinase C and Nuclear Factor-Kappa B signaling pathways mediate the upregulation of Intracellular Adhesion Molecule-1 induced by Chlamydophila pneumonia. Arterioscler Thromb Vasc Biol. 2003;23(5):a22, Abstract P121.
2. Sohani, A. R., Krings, G., Hasserjian, R.P., Pilch, B.Z., Harris, N.L., and Ferry, J.A. Extranodal NK/T-cell lymphoma nasal type with a predominance of small cells: Challenging diagnosis of a putative early lesion. European Association of Haematopathology (EAHP), 15th Annual Meeting, Uppsala, Sweden, 2010. [Poster]
3. Krings, G., Jain, D., Wu, T-T., Yeh, M., Torbenson, M., and Kakar, S. Immunohistochemical pitfalls and the importance of glypican-3 in the diagnosis of scirrhous hepatocellular carcinoma. Modern Pathology 2011;24 (suppl 1): 366A, Abstract #1553. Presented at United States and Canadian Academy of Pathology (USCAP), 100th Annual Meeting, San Antonio, Texas, 2011. [Poster]
4. Das, K., Krings, G., Pitman, M., and Mino-Kenudson, M. A novel monoclonal antibody, mAb Das-1, identifies a colonic phenotype and is specific for intraductal papillary mucinous neoplasm (IPMN) with a high risk for malignant transformation. Modern Pathology 2011;24 (suppl 1): 358A, Abstract #1519. Presented at United States and Canadian Academy of Pathology (USCAP), 100th Annual Meeting, San Antonio, Texas, 2011. [Poster]
5. Krings, G., Jain, D., Wu, T-T., Yeh, M., Torbenson, M., and Kakar, S. Immunohistochemical pitfalls and the importance of glypican-3 in the diagnosis of scirrhous hepatocellular carcinoma. Presented at UCSF Liver Center Symposium, March 11th, 2011, San Francisco, California. [Poster]
6. Krings, G., Ferrell, L., and Gill, R. Ki-67 and p53 expression as an immunohistochemical tool in the differential diagnosis of benign and malignant biliary lesions. Modern Pathology 2012;25 (supp 2): 416A, Abstract #1738. Presented at United States and Canadian Academy of Pathology (USCAP), 101st Annual Meeting, Vancouver, British Columbia, 2012. [Poster]<<<<
7. Can, B., Krings, G., and Ferrell, L. Arterialization and ductular metaplasia of centrizonal scars in chronic venous outflow obstruction: a frequently misinterpreted lesion. Modern Pathology 2012;25 (supp 2): 412A, Abstract #1720. Presented at United States and Canadian Academy of Pathology (USCAP), 101st Annual Meeting, Vancouver, British Columbia, 2012. [Poster]
8. Krings, G., Ferrell, L.F., and Gill, R.M. Ki-67 and p53 Expression as an Immunohistochemical Tool in the Differential Diagnosis of Benign and Malignant Biliary Lesions. Presented at UCSF Liver Center Symposium, June 15th, 2012, San Francisco, California. [Poster]
Prepared: February 11, 2019
21 of 27
9. Krings, G., Can, B., and Ferrell, L.F. Altered hepatic vascular and lobular organization near centrizonal scars in chronic venous outflow obstruction. Modern Pathology 2013;26 (supp 2s): 405A, Abstract #1692. Presented at United States and Canadian Academy of Pathology (USCAP), 102nd Annual Meeting, Baltimore, Maryland, 2013. [Poster]
10. Krings, G., Can, B., and Ferrell, L.F. Altered hepatic vascular and lobular organization near centrizonal scars in chronic venous outflow obstruction. Presented at UCSF Liver Center Symposium, April 12th, 2013, San Francisco, California. [Poster]
11. Mori, M., Krings, G., Chan, L., Wolf, D., Chen, Y-Y., Kerlikowske, K., Tlsty, T.D., Coppe, J-P., Matsuda, N., Suzuki, K., Nakamura, S., and van't Veer, L. Predictive biomarkers for invasion on final pathology in patients with preoperative diagnosis of ductal carcinoma in situ of the breast by needle biopsy. Presented at San Antonio Breast Cancer Symposium, San Antonio, Texas, 2013. [Poster]
12. Krings, G., Nystrom, M., Vohra, P., and Chen, Y-Y. Sensitivity and Utility of Commonly Used GATA3 Antibodies in Triple Negative Breast Cancers. Modern Pathology 2014;27 (supp 2): 61A, Abstract #235. Presented at United States and Canadian Academy of Pathology (UCSAP), 103rd Annual Meeting, San Diego, California, 2014. [Poster]
13. Firetag, B., Krings, G., Nystrom, M.J., Berry, A.B., Chen, Y-Y., and Balassanian, R. Aberrant Staining for Mesothelial Markers Calretinin and WT-1 in Triple Negative Breast Cancers. Modern Pathology 2014;27 (supp 2): 102A, Abstract #407. Presented at United States and Canadian Academy of Pathology (USCAP), 103rd Annual Meeting, San Diego, California, 2014. [Poster]
14. Mori, M., Krings, G., Chan, L., Wolf, D., Chen, Y-Y., Kerlikowske, K., Tlsty, T.D., Coppe, J-P., Matsuda, N., Suzuki, K., Nakamura, S., and van’t Veer, L. Predictive biomarkers of invasive carcinoma on excision in patients with a diagnosis of ductal carcinoma in situ of the breast by needle biopsy. J Clin Oncol 32, 2014 (suppl; abstr e12029).
15. Drukker K., Malkov S., Giger M., Joe B., Kerlikowske K., Drukteinis J., Wisner D., Pereira M., Kazemi L., Krings G., Patel B., and Shepherd J. Three-Compartment Breast Imaging and Quantitative Mammographic Image Analysis: Synergy for Improved Diagnosis. Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, Chicago IL. November 30th-December 5th. [Poster]
16. Bartelink, I.H., Prideau,x B., Hann, B., Krings, G., Coppe, J.P., Swigart-Brown, L., Lee, PRE, Esserman, L., Yee, D., Wolf, D., Savic, R.M., and van't Veer, L. Spatial distribution of veliparib measured by matrix assisted laser desorption ionization mass spectrometry in triple negative breast cancer tumors. Cancer Research 05/2015; 75(9 Supplement):P6-11-02-P6-11-02. J Clin Oncol 32, 2014 (suppl 26; abstr 161).Presented at San Antonio Breast Cancer Symposium, San Antonio, Texas, December 9th-13th, 2014 [Poster, P6-11-02].
17. Ng, D., Krings, G., Yau, C., White, K., Hou, J., Chua, A., Grenert, J.P., Chen, Y-Y. Alterations in HER2 status and outcome following neoadjuvant chemotherapy in HER2-positive breast cancer. Cancer Research 05/2015; 75(9 Supplement):P3-06-28-P3-06-28. Presented at San Antonio Breast Cancer Symposium, San Antonio, Texas, December 9th-13th, 2014. [Poster, P3-06-28]
18. Tsokos, C., Liu, X., Solomon, D., Chen, X., Hale, G., Seeley, E.S., Kakar, S., and Krings, G. Telomerase Reverse Transcriptase Promoter Mutations (mTERTp) in Combined Hepatocellular(HCC)-Cholangiocarcinoma(CC; cHCC-CC) Support Clonal and HCC-like
Prepared: February 11, 2019
22 of 27
Origin for Both Components. Modern Pathology 2015;28(supp 2): 425A, Abstract #1697. Presented at United States and Canadian Academy of Pathology (USCAP), 104th Annual Meeting, Boston, Massachusetts, 2015. [Poster] Hans Popper Hepatopathology Society Best Trainee Abstract Award, runner-up.
19. Krings, G., Ng, D., Hou, J., Chua, A., Grenert, J.P., Chen, Y-Y. Immunophenotypic Switching of Biomarkers (IS) in Breast Cancer (BC) After Neoadjuvant Chemotherapy (NCT). Modern Pathology 2015;28(supp 2): 52A, Abstract #196. Presented at United States and Canadian Academy of Pathology (USCAP), 104th Annual Meeting, Boston, Massachusetts, 2015. [Poster]
20. Krings, G. and Chen, Y-Y. Diagnostic Sensitivity and Utility of GATA3 in Breast Cancer (BC) After Hormonal (HT) and Chemotherapy (CT). Modern Pathology 2015;28(supp 2): 52A, Abstract #195. Presented at United States and Canadian Academy of Pathology (USCAP), 104th Annual Meeting, Boston, Massachusetts, 2015. [Poster]
21. Krings, G. and Chen, Y-Y. SATB2 Expression in Metaplastic Carcinoma of the Breast (MCB) with Osseous Differentiation (OD). Modern Pathology 2015;28(supp 2): 52A, Abstract #197. Presented at United States and Canadian Academy of Pathology (USCAP), 104th Annual Meeting, Boston, Massachusetts, 2015. [Poster]
22. Ballard, M., Jalikis, F.G, Krings, G., Schmidt, R., Chen, Y-Y., Rendi, M.H., Dintzis, S.M., Jensen, K.C., West, R., Sibley, R., and Allison, K.H. Characterization of Breast Cancers with Equivocal and Non-Classical HER2 FISH Results; A Multi-Institutional Study. Modern Pathology 2015;28(supp 2): 35A, Abstract #128. Presented at United States and Canadian Academy of Pathology (USCAP), 104th Annual Meeting, Boston, Massachusetts, 2015. [Platform]
23. O'Meara, T., Campbell, M.J., Mukhtar, R., Obi-Okoye, E., Han, B., Tandon, V., Zheng, S., Zhu, Z., Endicott, M., Wicha, M., Lindstrom, L., Krings, G., Au, A., Baehner, F., Gray, J., and Esserman, L. Characterizing the Tumor Immune MicroEnvironment (TIME) in high-risk ductal carcinoma in situ. Presented at UCSF Breast Oncology Program Scientific Retreat, 2015 [Poster]
24. Brown Swigart, L., Glenn, P., Ma, A. A., Dean, L. Etzel, K., Griffin, L., Sheshadri, V., Dargis, B., Santos, C., Au, A., Balassanian, R., Chen, Y.-Y., Krings, G., Esserman, L., and van 't Veer, L.The I-SPY 2 TRIAL: Serial sample collection for biomarker studies and early identification of non-reponders. Presented at UCSF Breast Oncology Program Scientific Retreat, 2015 [Poster]
25. Bartelink, I.H., Prideaux, B., Krings, G., Wilmes, L., Lee, P.R.E.,Hann, B., Coppé, J.-P., Heditsian, D., Swigart-Brown, L., Jones, E.F., Magnitsky, S., Keizer, R., Esserman, L., Ruan, W., Wu, A., Yee, D., Dartois, V., Wolf, D., Savic, S., and VantVeer, L. Non-homogeneous drug penetrance of veliparib measured in triple negative breast tumors. Mol Cancer Ther December 2015 14; C61. Presented at American Association for Cancer Research (AACR)-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA, November 2015. [Poster]
26. Goga, A., Camarda, R., Zhou, A.Y., Kohnz, R.A., Balakrishnan, S., Anderton, B., Mahieu, C., Eyob, H., Krings, G., and Nomura, D.K. Inhibition of fatty-acid oxidation as a therapy for triple-negative breast cancer. Cancer Res February 15, 2016 76; PD3-05. Presented at 38th Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 8-12, 2015; San Antonio, TX
Prepared: February 11, 2019
23 of 27
27. Drukker, K., Malkov, S., Avila, J., Kerlikowske, K., Joe, B., Krings, G., Creasman, J., Drukteinis, J., Pereira, M. M., Kazemi, L., Shepherd, J., and Giger, M.L. Identification, segmentation, and characterization of microcalcifications on mammography. Accepted for presentation at SPIE Medical Imaging, San Diego, CA, 2016.
28. Camarda, R., Zhou, A.Y., Kohnz, R.A., Balakrishnan, S., Anderton, B., Mahieu, C., Eyob, H., Tward, A., Krings, G., Nomura, D.K., and Goga, A. Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer. Presented at UCSF Breast Oncology Program Scientific Retreat, San Francisco, CA, 2016. [Poster]
29. Bartelink. I.H., Prideaux, B., Krings, G., Wilmes, L., Lee, P.R., Hann, B., Coppé, J., Heditsian, D., Swigart-Brown, L., Jones, E.F., Magnitsky, S., Keizer, R., Esserman, L., Ruan, W., Wu, A., Yee, D., Dartois, V., Wolf, D., Savic, R., and Vant Veer, L. Nonhomogenous drug penetrance of Veliparib measured in triple negative breast tumors. Clin Pharmacol Therapeut 2016;99(Supp S1):S5–S107. Presented at the ASCPT 2016 Annual Meeting & Quantitative Translational Approaches in Oncology Pre-Conference, San Diego, CA, March 8th 2016.
30. Vohra, P., Krings, G., Vohra, M., and Chen, Y.-Y. Correlation of OncotypeDx Recurrence Score with IHC3/IHC4 and Grade in Ductal Carcinoma in Situ (DCIS). Modern Pathology 2016;29(supp 2):76A, Abstract #299. Presented at United States and Canadian Academy of Pathology (USCAP), 105th Annual Meeting, Seattle, WA, 2016. [Poster]
31. Borowsky, A., Lindstrom, L.S., Thompson, C. K., Balassanian, R., Yau, C., Chen, Y.-Y., Krings, G., Nordenskjold, B., Stal, O., Fornander, T., Esserman, L., Vant Veer, L. Phenotype and Immunophenotype Analysis of Gene Expression Defined "Indolent Risk" Breast Cancers. Modern Pathology 2016;29(supp 2):33A, Abstract #122. Presented at United States and Canadian Academy of Pathology (USCAP), 105th Annual Meeting, Seattle, WA, 2016. [Platform]
32. Borowsky, A., Balassanian, R., Chen, Y-Y., Krings, G., Zhang, Y., Carpenter, P., Bishop, J., Datnow, B., Hosteh, F., Rellatak, H., Engleberg, J., Cardiff, R., Lindstrom, L., Thompson, C., Yau, C. Interobserver Agreement of Breast Cancer Quantitative IHC Measured After “Score the Core” Training. Modern Pathology 2016;29(supp 2):33A, Abstract #121. Presented at at United States and Canadian Academy of Pathology (USCAP), 105th Annual Meeting, Seattle, WA, 2016. [Poster]
33. Ladwig, N., Joseph, N., Zaloudek, C., Rabban, J., Krings, G., and Garg, K. Molecular characterization of high grade endometrial stromal sarcoma. Modern Pathology 2016;29(supp 2):293A, Abstract #1165. Presented at United States and Canadian Academy of Pathology (USCAP), 105th Annual Meeting, Seattle, WA, 2016. [Poster]
34. Liu, S.-Y., Joseph, N., Chen, Y.-Y., Vohra, P., and Krings, G. Analysis of Malignant Phyllodes Tumor Genomic Landscape Using Capture-based Next Generation Sequencing. Modern Pathology 2016;29(supp 2):55A, Abstract #213. Presented at United States and Canadian Academy of Pathology (USCAP), 105th Annual Meeting, Seattle, WA, 2016 [Poster]
35. Liu, S.-Y., Chen, Y.-Y., Joseph, N., Vohra, P., and Krings, G. Analysis of MED12 and TERT Promoter Mutations in Fibroepithelial Lesions, Metaplastic Carcinomas and Spindle Cell Lesions of the Breast. Modern Pathology 2016;29(supp 2):55A, Abstract #214. Presented at United States and Canadian Academy of Pathology (USCAP), 105th Annual Meeting, Seattle, WA, 2016. [Poster]<<
Prepared: February 11, 2019
24 of 27
36. Krings, G., Joseph, N.M., Bean, G.R., Onodera, C., Talevich, E., Yeh, I., Jordan, R., Grenert, J.P., Hosfield, E., Zaloudek, C., Van Zante, A., Shin, S.J., and Chen, Y-Y. Genomic Profiling of Secretory Carcinoma. Presented at United States and Canadian Academy of Pathology (USCAP), 106th Annual Meeting, San Antonio, 2017. [Platform]
37. Krings, G., Chen, Y-Y., and Jen, K-Y. Genomic Profiling of Synchronous Bilateral Lobular Carcinoma. Presented at United States and Canadian Academy of Pathology (USCAP), 106th Annual Meeting, San Antonio, 2017. [Poster]
38. Shamir, E., Chu, T., Rabban, J.T., Chen, Y-Y., and Krings, G. Clinicopathologic Review of Non-Classic Lobular Carcinoma In Situ Variants at a Single Academic Center. Presented at United States and Canadian Academy of Pathology (USCAP), 106th Annual Meeting, San Antonio, 2017. [Platform]
39. Ruiz, J., Krings, G. and Chen, Y-Y. Genomic Profiling of Apocrine Carcinoma of the Breast. Presented at United States and Canadian Academy of Pathology (USCAP), 106th Annual Meeting, San Antonio, 2017. [Platform]
40. Bean, G.R., Pekmezci, M., Chen, Y-Y., Hwang, E.S., and Krings, G. H3K27me3 Expression and X Chromosome Inactivation in Breast Carcinoma. Presented at United States and Canadian Academy of Pathology (USCAP), 106th Annual Meeting, San Antonio, 2017. [Poster]
41. Han, L. Chen, Y-Y., Krings, G., Mak, J., and Rabban, J.T. Occult Malignancy in Risk Reduction Bilateral Mastectomies from Women with BRCA1 or BRCA2 Germline/> Mutation: Correlation with Imaging Abnormalities and Implications for Specimen Sampling Strategies. Presented at United States and Canadian Academy of Pathology (USCAP), 106th Annual Meeting, San Antonio, 2017. [Poster]
42. Bean, G.R., Krings, G., and Garg, K. DICER1 Mutations in Müllerian Adenosarcomas. Presented at United States and Canadian Academy of Pathology (USCAP), 106th Annual Meeting, San Antonio, 2017. [Poster]
43. Cohen J., Bowman, S., Szabo, G., Umetsu, S.E., Krings, G., and Laszik, Z. Discordant Expression of cMYC and PD-L1 in Various Human Tumors. Presented at United States and Canadian Academy of Pathology (USCAP), 106th Annual Meeting, San Antonio, 2017. [Poster]
44. Korn, W.M., Yeh, I., Van Ziffle, J., Grenert, J.P., Joseph, N., Solomon, D., Laurance, A., Talevich, E., Onodera, C., Krings, G., Stohr, B.A., Blanco, A., and Bastian, B.C. Targeted next-generation DNA sequencing of paired tumor and normal DNA to reveal frequent actionable germline alterations. American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June 3rd, 2017. [Poster] J. Clin Oncol. 35(15): Abstract 11575.
45. Greenwood, H. Joe, B., Niell, B., Creasman, J., Giger, M., Drukker, K., Malkov, S., Kerlikowske, K., Drukteinis, J., Krings, G., and Shepherd, J. Use of three-compartment dual energy mammography in reducing false positive breast biopsies. Accepted for presentation at Radiological Society of North America Meeting, Chicago IL, 2017. [Poster]
46. Benz, C., Yau, C., Benz, S., Krings, G., Powell, M. Normal breast biopsies reveal an "active" transcriptome associating with higher breast cancer risk (Gail) scores and increased IGF1 growth factor expression. San Antonio Breast Cancer Symposium, San Antonio, Texas, 2017 [Poster] Cancer Research 78(4 Supplement):P3-10-05-P3-10-05 · February 2018 DOI: 10.1158/1538-7445.SABCS17-P3-10-05
Prepared: February 11, 2019
25 of 27
47. Yee, D., DeMichele, A., Isaacs, C., Symmans, F., Yau, C., Albain, K.S., Hylton, N.M., Forero-Torres, A., Van't Veer, L.J., Perlmutter, J., Rugo, H.S., Melisko, M., Chen, Y.-Y., Balassanian, R., Krings, G.,... Esserman, L.J. Pathological complete response predicts event-free and distant disease-free survival in the I-SPY2 TRIAL. Abstract #700078. San Antonio Breast Cancer Symposium, San Antonio, Texas, 2017. [oral presentation]
48. Hwang, E.S., Hyslop, T., Duong, S., Bedrosian, I., Wisner, D., Price, E., Caudle, A., Guenther, J., Hudis, C., Winer, E., Lyss, A.P.,Dickson-Witmer, D., Hieken, T., Hoefer, R., Ollila, D.W., Dickler, M., Hardman, T., Chen, Y-Y., Krings, G., Esserman, L. and Hylton, N. Phase II Single Arm Study of Preoperative letrozole for ER(+) Postmenopausal DCIS Alliance/CALGB 40903. San Antonio Breast Cancer Symposium, San Antonio, Texas, 2017. [oral presentation]
49. Cohen, J., Sabnis, A.J., Grenert, J.P., Krings, G., Cho, S.J. Horvai, A. and Davis, J.L. EWSR1-NFATC2 Gene Fusions Define A Group of Undifferentiated Tumors in Bone and Soft Tissue with Round and Epithelioid Morphology. Abstract #91. United States and Canadian Academy of Pathology (USCAP), 107th Annual Meeting, Vancouver, British Columbia, 2018. [poster]
50. Krings, G. and Chen, Y-Y. Genomic Profiling of Metaplastic Carcinoma and Associated in Situ Carcinoma of the Breast. Abstract #943. United States and Canadian Academy of Pathology (USCAP), 107th Annual Meeting, Vancouver, British Columbia, 2018. [platform]
51. Krings, G., Bean, G., Stohr, B., Hosfield, E., Shin, S.J., and Chen, Y-Y. Molecular Characterization of Mammary Pleomorphic Adenomas. Abstract #1366. United States and Canadian Academy of Pathology (USCAP), 107th Annual Meeting, Vancouver, British Columbia, 2018. [poster]
52. Shamir, E., Chu, T., Chen, Y-Y., and Krings, G. Genomic Profiling of Lobular Carcinoma in Situ (LCIS) Variants with Comparison to Classic LCIS and Invasive Lobular Carcinoma. Abstract #1386. United States and Canadian Academy of Pathology (USCAP), 107th Annual Meeting, Vancouver, British Columbia, 2018. [platform]
53. Bean, G., Shin, S.J., Hosfield, E., Jones, K., Chen, Y-Y., and Krings, G. Molecular Characterization of Small Cell/Neuroendocrine Carcinomas of the Breast. Abstract #1610. United States and Canadian Academy of Pathology (USCAP), 107th Annual Meeting, Vancouver, British Columbia, 2018. [poster]
54. Ballard, M., MacKerricher, W., Jalikis, F., Krings, G., Schmidt, R., Chen, Y-Y., Rendi, M., Dintzis, S., Troxell, M., West, R., Sibley, R., and Allison, K. Potential Impact of Proposed HER2 FISH Guideline Updates on FISH results; A Multi-Institutional Study. Abstract #2509. United States and Canadian Academy of Pathology (USCAP), 107th Annual Meeting, Vancouver, British Columbia, 2018. [poster]
55. Ballard, M., Toukatly, M., Bean, G., Jalikis, F., Krings, G., Schmidt, R., Chen, Y-Y., Dintzis, S., Troxell, M., West, R., Sibley, R., and Allison, K. Pathologic features and clinical outcomes of HER2 FISH cases with HER2:CEP17 ratio > 2.0 but < 4 HER2 signals/cell; A Multi-Institutional study. Abstract #2656. United States and Canadian Academy of Pathology (USCAP), 107th Annual Meeting, Vancouver, British Columbia, 2018. [platform]
56. Ballard, M., Toukatly, M., Bean, G., Jalikis, F., Krings, G., Schmidt, R., Chen, Y-Y., Rendi, M., Dintzis, S., Troxell, M., West, R., Sibley, R., and Allison, K.Pathologic Features and Clinical Outcomes of Breast Cancers with HER2/CEP17 ratio <2.0 and mean HER2 signals /cell >6.0 by FISH; A Multi-Institutional Study. Abstract #2663. United States and
Prepared: February 11, 2019
26 of 27
Canadian Academy of Pathology (USCAP), 107th Annual Meeting, Vancouver, British Columbia, 2018. [poster]
57. Vohra, P., Krings, G., Chu, T., and Chen, Y-Y. Clinical and Pathologic Features of Invasive Breast Cancers with OncotypeDx Recurrence Score Less Than 11. Abstract #2849. United States and Canadian Academy of Pathology (USCAP), 107th Annual Meeting, Vancouver, British Columbia, 2018. [poster]
58. Mamounas, M., Wong, J., Farhner-Scott, K., Chen, Y-Y., Krings, G., Ewing, C., Esserman, L., Alvarado, M., Rugo, H., and Mukhtar, R. The impact of mitotic score versus pleomorphic subtype on disease free survival in invasive lobular carcinoma of the breast. The American Society of Breast Surgeons 19th Annual Meeting, May 2-6, 2018, Orlando, FL. [poster]
59. Mamounas, M., Wong, J., Farhner-Scott, K., Chen, Y-Y., Krings, G., Ewing, C., Esserman, L., Alvarado, M., Rugo, H., and Mukhtar, R. The impact of mitotic score versus pleomorphic subtype on disease free survival in invasive lobular carcinoma of the breast. European Breast Cancer Conference (EBCC), March 23rd, 2018, Barcelona, Spain [Poster]
60. Symmans, W.F., Yau, C., Chen, Y-Y., Datnow, B., Wei, S., Feldman, W.D., Ritter, J., Duan, X., Chen, B., Tickman, R., Sattar, H., Magliocco, A.M., Kallakury, B., Troxell, M., Asare, S., Liu, M.C., DeMichele, A., Yee, D., Berry, D.A., Esserman, L. on behalf of I-SPY 2 TRIAL Investigators and Pathologists. Residual cancer burden (RCB) is prognostic in the I-SPY 2 TRIAL Abstract #520, American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, 2018 [Poster]
61. Camarda, R., Williams, J., Malkov, S., Zimmerman, L.J., Manning, S., Aran, D., Beardsley, A., Van de Mark, D., van Haren, J., Chen, Y., Berdan, C., Louie, S., Mahieu, C., Winkler, J., Willey, E., Gagnon, J.D., Shinoda, K., Ansel, K.M., Werb, Z., Nomura, D.C., Kajimura, S., Wittmann, T., Butte, A.J., Sanders, M.E., Liebler, D.C., Krings, G., Shepherd, J.A., and Goga, A. Tumor cell-adipocyte gap junctions activate lipolysis in breast cancer. Abstract 2398. July 2018 Cancer Research 78(13 Supplement):2398-2398 DOI: 10.1158/1538-7445.AM2018-2398
62. Shah, K.N., Bhatt, R., Rotow, J., Rohrberg, J., Olivas, V., Hemmati, G., Krings, G., Haringsma, H.J., Simmons, A.D., Harding, T.C., Goga, A., Blakely, C., Bivona, T., and Bandyopadhyay, S. Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer. Abstract 1957.July 2018 Cancer Research 78(13 Supplement):1957-1957 DOI: 10.1158/1538-7445.AM2018-1957
63. Fowler, E. Harrison, B.T., Chen, Y.-Y., Krings, G., Vincent-Salomon, A., Fuhrmann, L., Chen, B., Hosfield, E.M., Barnick, S.E, Hornick, J.L., and Schnitt, S.J. Immunohistochemical Evaluation of Pan-TRK in Secretory Breast Carcinoma. #1585. United States and Canadian Academy of Pathology (USCAP), 108th Annual Meeting, National Harbor, Maryland, 2019. [platform talk, accepted]
64. Krings, G., Shamir, E.R., and Chen, Y.-Y. Genetics of Flat Epithelial Atypia and Early Neoplastic Progression in the Breast. #1018. United States and Canadian Academy of Pathology (USCAP), 108th Annual Meeting, National Harbor, Maryland, 2019. [platform talk, accepted]
65. Shamir, E.R., Vohra, P., Bean, G., Zaloudek, C., McCalmont, T.H.., Joseph, N.M., Wolsky, R.J., Garcia, J.J., Chen, Y.-Y., and Krings, G. Genomic Profiling of Basaloid Breast
Prepared: February 11, 2019
27 of 27
Carcinomas Reveals Recurrent Alterations in CREBBP and Distinct Genetics from Other Triple Negative Breast Cancers. #813. United States and Canadian Academy of Pathology (USCAP), 108th Annual Meeting, National Harbor, Maryland, 2019. [platform talk, accepted]
66. Van Ziffle, J. Devine, W.P., Onodera, C., Korn, W.M., Yeh, I., Grenert, J.P., Joseph, N., Solomon, D.A., Laurance, M., Talevich, E., Bean, G., Krings, G., Stohr, B.A., Umetsu, S., Blanco, A., Bastian, B.C. Sequencing of paired tumor and normal DNA samples with the UCSF500 targeted next-generation cancer gene panel reveals frequent actionable germline alterations. American College of Medical Genetics (ACMG) Annual Meeting, Seattle, Washington, 2019. [poster, accepted]
OTHER CREATIVE ACTIVITIES
1. Lazarchick, J. and Krings, G. (2007) Anaplastic large cell lymphoma involving the bone marrow. American Society of Hematology Image Bank Jul 2007: 6-00055. Lazarchick, J. and Krings, G. (2007) Anaplastic large cell lymphoma - nodal involvement. American Society of Hematology Image Bank Jul 2007: 6-00059. Krings, G. (2015) Fibroepithelial Lesions of the Breast: Review and Update (syllabus). UCSF Current Issues in Anatomic Pathology, CME activity. Krings, G. (2016) Solid Pattern Proliferations of the Breast (syllabus). UCSF Current Issues in Anatomic Pathology, CME activity. Krings, G. (2018) Updates on Diagnosis and Management of Borderline Breast Lesions on Core Needle Biopsy (syllabus). UCSF Current Issues in Anatomic Pathology, CME activity.
Top Related